Document Detail


Clobazam therapy of refractory epilepsy in tuberous sclerosis complex.
MedLine Citation:
PMID:  23219029     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Clobazam (CLB) was recently approved by the FDA, but has not been evaluated in tuberous sclerosis complex (TSC). We retrospectively reviewed a cohort of patients with TSC and refractory epilepsy who started CLB over a 5-year period. Clinical characteristics and number of tubers on MRI were assessed. Duration of therapy, therapeutic response and adverse events were recorded. CLB was prescribed in 29 adults and children of whom 72% were cognitively impaired, with a median age at seizure onset of 5 months. Mean duration of CLB therapy was 17.3 months with a 12 and 24-month estimated retention rate of 82% and 68%, respectively. Twenty patients (69%) reported a good response (>50% seizure reduction) at the end of the titration, and six patients (21%) remained good responders after 12 months of CLB therapy. Adverse events occurred in 13 patients, predominantly somnolence and behavioral disorders. One quarter of the responders reported improvement in behavior. No predictive factor for a good response could be identified. CLB appears to be a well-tolerated and valuable option for treatment of refractory epilepsy in TSC.
Authors:
Melanie Jennesson; Agnies M van Eeghen; Paul A Caruso; Jan L Paolini; Elizabeth A Thiele
Related Documents :
23258519 - Radiosurgery of brain cavernomas - long-term results.
8725709 - Comparison of two warfarin regimens in the prevention of venous thrombosis following to...
3352289 - Valve prostheses in children: a reassessment of anticoagulation.
1273529 - A controlled investigation of the value of anticoagulant therapy in cases of prostatect...
23219029 - Clobazam therapy of refractory epilepsy in tuberous sclerosis complex.
7034479 - Oral anticoagulation in the secondary prevention of myocardial infarction.
16898369 - Causes of death during tuberculosis treatment in tomsk oblast, russia.
20063449 - Does intrafascial dissection during nerve-sparing laparoscopic radical prostatectomy co...
22310839 - Prospective evaluation of voice outcome during the first two years in male patients tre...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-12-03
Journal Detail:
Title:  Epilepsy research     Volume:  104     ISSN:  1872-6844     ISO Abbreviation:  Epilepsy Res.     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-30     Completed Date:  2013-11-14     Revised Date:  2013-12-05    
Medline Journal Info:
Nlm Unique ID:  8703089     Medline TA:  Epilepsy Res     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  269-74     Citation Subset:  IM    
Copyright Information:
Copyright © 2012. Published by Elsevier B.V.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Anticonvulsants / therapeutic use*
Benzodiazepines / therapeutic use*
Child
Child, Preschool
Epilepsy / complications,  drug therapy*
Humans
Male
Retrospective Studies
Treatment Outcome
Tuberous Sclerosis / complications*,  drug therapy
Young Adult
Chemical
Reg. No./Substance:
0/Anticonvulsants; 12794-10-4/Benzodiazepines; 2MRO291B4U/clobazam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reduced densities of parvalbumin- and somatostatin-expressing interneurons in experimental cortical ...
Next Document:  Involvement of ?4?2 nicotinic acetylcholine receptors in working memory impairment induced by repeat...